Investigational KRAS vaccine shows immune response in pancreatic cancer trial

Source Summary

An investigational vaccine enabled the immune system to recognize and respond to KRAS mutations that drive most pancreatic cancers, according to a randomized phase 2 clinical trial led by Mayo Clinic researchers. The results, published in Nature Medicine, will inform the design of a larger phase 3 trial.

Why it matters

The vaccine's ability to generate immune recognition of KRAS mutations represents a potential therapeutic approach for pancreatic cancer, one of the most lethal malignancies, and establishes a foundation for larger clinical testing.